Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Benralizumab for uncontrolled asthma – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Benralizumab is intended to be used as second line therapy for the treatment of patients with uncontrolled asthma. If licensed, benralizumab will offer an additional treatment option for patients with this condition. Benralizumab is a fully humanised anti-interleukin-5 receptor (IL-5R) monoclonal antibody which blocks the binding of IL-5 to the specific α-chain of the IL-5 receptor. IL-5 stimulates the production, activation and maturation of eosinophils, which is thought to contribute to airway inflammation and lung tissue remodelling. Benralizumab does not currently have Marketing Authorisation in the EU for any indication.
In the UK around 5.4 million people are receiving treatment for asthma; the equivalent of 1 in 12 adults and 1 in 11 children. Approximately 5% of asthma sufferers are described as therapy resistant and are unable to get good control of their asthma despite using high levels of anti-asthma medicines. There are between 1,000 and 1,200 deaths from asthma each year in the UK, with premature mortality from asthma reported to be 1.5 times higher in the UK compared to the rest of Europe.
The management of asthma aims to control the disease while minimising adverse reactions to treatment; good control is characterised by no daytime symptoms, no night-time awakening due to asthma, normal lung function, no need for rescue medication, no exacerbations, and no limitations on activity including exercise. Benralizumab is currently in multiple phase III clinical trials comparing its effect on forced expiratory volume in 1 second (FEV1), annual asthma exacerbation rate and reduction in oral corticosteroid dose against treatment with placebo. These trials are expected to complete by Q1 2016. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Asthma; Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000392 Date abstract record published 04/03/2016 |